Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

When to switch and what to switch to: strategic use of antiretroviral therapy.

The AIDS reader - 1 Mar 2000

Gulick R

Abstract excerpt

Clinical cohort studies suggest that as many as 60% of patients experience virologic failure of a first-line antiretroviral regimen. Second-line and rescue (or salvage) regimens have a poorer success record: Most studies presented to date show a short-term virologic response rate of only approxim...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carbamates
Share to Dideoxynucleosides
Share to Furans

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Indinavir

Share to Lopinavir

Share to Nelfinavir

Share to Pyrimidinones

Share to Retroviridae Infections

Source

Identifiers

PMID: 10758015

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-10758015-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

When to switch and what to switch to: strategic use of antiretroviral therapy.PMID 10758015Read ↗

When to switch for antiretroviral treatment failure in resource-limited settings?Semantic proximity Read ↗

Salvage therapy: still more intuition than data.Semantic proximity Read ↗

Management of antiretroviral therapy for HIV infection: modelling when to change therapy.Semantic proximity Read ↗

Maraviroc, as a Switch Option, in HIV-1–infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH StudySemantic proximity Read ↗

Switching to coformulated bictegravir, emtricitabine, and tenofovir alafenamide maintained viral suppression in adults with historical virological failures and K65N/R mutation.Semantic proximity Read ↗

Virologic Outcomes of Switching to Dolutegravir Functional Monotherapy, or Functional Dual Therapy With Dolutegravir Plus A Non-cytosine Nucleoside Analog: A Retrospective Study of Treatment-Experienced, HIV-1 Infected PatientsSemantic proximity Read ↗

Efficacy and HIV drug resistance profile of second-line ART among patients having received long-term first-line regimens in rural China.Semantic proximity Read ↗

HIV treatment simplification : outcomes of switching HIV-1 patients to protease-inhibitor maintenance monotherapySemantic proximity Read ↗

Efficacy of initial antiretroviral therapy for HIV-1 infection in adults: a systematic review and meta-analysis of 114 studies with up to 144 weeks' follow-up.Semantic proximity Read ↗

Virological Outcome After Choice of Antiretroviral Regimen Guided by Proviral HIV-1 DNA Genotyping in a Real-Life Cohort of HIV-Infected Patients.Semantic proximity Read ↗

Virological Failure After Switch to Long-Acting Cabotegravir and Rilpivirine Injectable Therapy: An In-depth Analysis.Semantic proximity Read ↗

Viral suppression following switch to second-line antiretroviral therapy: associations with nucleoside reverse transcriptase inhibitor resistance and subtherapeutic drug concentrations prior to switch.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.